• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regeneron, Sanofi tout topline Ph3 data for injectable asthma drug

September 11, 2017 By Sarah Faulkner

Regeneron, SanofiSanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) touted data today from the pivotal Phase III trial of dupilumab in a group of patients with uncontrolled, persistent asthma.

The drug is already approved for adults with certain forms of eczema. The two companies said they plan to seek FDA approval of dupilumab in asthma by the end of the year.

The Quest trial met its two primary endpoints, which included the yearly rate of severe exacerbation events after 1 year and the absolute change from baseline in pre-bronchodilator forced expiratory volume over one second at 12 weeks.

Dupilumab, which is an injectable monoclonal antibody, reduced severe asthma attacks and boost lung function when added to standard therapies, according to the data. After 1 year, in the group receiving 300 milligrams of the drug, dupilumab cut severe asthma attacks by 46% in the overall population.

The drug worked even better in patients with higher counts of a white blood cell commonly found in patients who have a hard time controlling their asthma – eosinophils. Patients with 150 eosinophilic cells per microliter of blood experienced a 60% cut in severe asthma attacks and an 11% increase in lung function.

Study participants with 300 eosinophilic cells per microliter saw a 67% reduction in severe asthma attacks and an 18% boost in lung function, the companies touted.

“Approximately one million U.S. adults and adolescents live with uncontrolled, persistent asthma, and continue to experience serious asthma attacks, despite taking an intensive regimen of standard therapies,” Regeneron president & chief scientific officer Dr. George Yancopoulos said in prepared remarks. “Dupilumab has now demonstrated positive late-stage results in two serious allergic diseases – asthma and atopic dermatitis – with robust efficacy and an extensive safety database. These results continue to support our hypothesis that the IL4/IL13 pathway is a critical driver of allergic disease, and we remain committed to further investigating the IL-4/IL-13 pathway in other allergic diseases.”

“We believe that therapies like dupilumab, which focus on specific molecular pathways such as the Th2 pathway associated with multiple chronic allergic diseases, are important targets for further investigation,” Dr. Elias Zerhouni, Sanofi’s president of global R&D, added. “The positive data from this large second pivotal trial in uncontrolled persistent asthma, following the positive results of dupilumab in atopic dermatitis, further support this view in our opinion. We will work diligently with health authorities to bring this new application of dupilumab to the patients who most need it.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Regeneron, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS